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Introduction
Pulmonary arterial hypertension (PAH) is a devastating and progressive disease of the pulmonary circulation, characterized by increasing pulmonary vascular resistance leading to right ventricular failure and premature death. 1 Current treatment paradigms for PAH focus on three therapeutic classes: endothelin receptor antagonists (ERAs), phosphodiesterase type-5 inhibitors (PDE-5Is), and prostacyclin or its analogues. 1, 2 The major pharmacological actions of the prostacyclin analogues in the context of PAH include: vasodilatation of the pulmonary and systemic vascular beds, inhibition of platelet aggregation, and inhibition of smooth muscle cell proliferation. 3, 4 Parenteral prostacyclin therapy has been shown to improve hemodynamics and exercise capacity, delay clinical worsening, and improve survival in PAH patients. [5] [6] [7] [8] [9] [10] Due to the relative complexity and administration challenges of continuous intravenous or subcutaneous infusions, however, parenteral prostacyclin analogue therapy has been typically reserved for the treatment of more advanced disease. 1 Given the established safety and efficacy profile of approved prostacyclin analogue therapies, there has been interest in developing analogues amenable to inhaled or oral use. 1, 8, 11 In fact, inhaled prostacyclin analogues have emerged as attractive treatment options, especially as part of second-line combination therapies, due to their relatively low incidence of systemic side effects and relative ease of use compared to parenteral therapy. [12] [13] [14] [15] [16] [17] The development of effective oral prostacyclin analogues, however, has proven more challenging. While the initial clinical results for the first-in class oral prostacyclin, beraprost, were encouraging, follow-up studies were unsuccessful and the compound never gained regulatory approval in the United States or Europe. 18, 19 Treprostinil is a chemically stable prostacyclin analogue with demonstrated safety and exercise capacity, delay clinical worsening, and improve survival in PAH patien nt ts ts. 5-1 5-1 5-10 0 0 D D Due ue ue t t to o o t the elative complexity and administration challenges of continuous intravenous or subcutaneous n nfu fu usi si sion on ons, s, h h how ow wev v ver er er, , parenteral prostacyclin anal log og o u u ue therapy has s b b been n ty ty typi p cally reserved for the r rea a atm tment of m mor or re ad d dv v van nc nced ed ed d d di is isea ea ase se se. 1 Gi Give ve ven n n th the e e e es esta tabl blis is i he h d d d sa sa afe fe fety ty ty a an nd nd e e eff ff ffi i icac ac acy y p pr prof ofi il ile e of of of a app pp ppro ro ove ve ed d d p pr pro os sta tacy cy cycl cl c in in n a a an n nalo lo ogu gu gue e herapies, the ere re re h has as as b b bee ee e n n n in n nte te tere r r st st st i i in n de d d ve ve velo lo lopi pi ping ng ng a ana na nalo lo ogu gu g es es es am am amen en enab ab a le e e t t to o o in in inha ha hale le l d d d or or or o o ora ra ral l use. 1 1 1, 8 8 8, 11 11 11 by guest on July 25, 2017 http://circ.ahajournals.org/ Downloaded from efficacy when administered by intravenous, subcutaneous, or inhaled routes of administration. 7, 16, 20 The sodium salt of treprostinil is currently approved for the treatment of PAH for either parenteral (Remodulin®) or inhaled (Tyvaso®) routes of administration. 21, 22 Treprostinil diolamine (UT-15C; also referred to as treprostinil diethanolamine) is a treprostinil salt amenable to oral administration. In the blood stream, both treprostinil sodium and treprostinil diolamine rapidly dissociate to the freely ionized form of treprostinil. Thus, the therapeutic use of oral treprostinil diolamine builds on the substantial clinical experience of parenteral and inhaled treprostinil sodium.
Treprostinil diolamine tablets are formulated as extended-release, osmotic tablets to support twice daily (BID) oral administration. In pharmacokinetic studies involving PAH patients on chronic, open-label therapy, treprostinil diolamine demonstrated a terminal half-life of approximately 4.5 hours with a broad and sustained blood concentration for 8-10 hours following a single oral dose. 23 Oral treprostinil diolamine is primarily subject to CYP2C8 and, to a lesser extent, CYP2C9 metabolism and demonstrates increased bioavailability with food. 24, 25 In PAH patients, an oral treprostinil dose of 3.5 mg BID produced plasma levels between 2-8 hours post-dose comparable to those seen with parenteral infusion rates of 10-30 ng/kg/min. 23 The first completed study with oral treprostinil (FREEDOM-C) failed to meet its primary endpoint. In that 16-week, randomized, placebo-controlled study, PAH patients receiving approved background therapy (ERA, PDE-5I, or both) treated with oral treprostinil therapy had a non-significant increase in 6-minute walk distance (6MWD) of 11 m (p=0.07). 26 However, FREEDOM-C patients were initiated on study drug at a starting dose of oral treprostinil (1 mg BID) that was later linked to poor tolerability and a relatively high rate of discontinuations due to adverse event (AE). Lower strength tablets (0.25 and 0.5 mg) were subsequently developed with upport twice daily (BID) oral administration. In pharmacokinetic studies involv vi in ing g g PA PA AH H H patients on chronic, open-label therapy, treprostinil diolamine demonstrated a terminal half-life of f a a app pp ppr ro roxi xi xima ma mate t ly ly y 4 4 4.5 .5 hours with a broad and sus s st ta tain n ned blood con nce ce c ntra ra ati ti tio on for 8-10 hours f fo oll lo ow o ing a si ing ngle l l ora ral l do do dose se se. . 23 23 23 O Ora ra al l tr tre ep pr r rosti i ini i il dio ol la am mi min ne ne i is s s p pr prim im ma ar ril ily y su subj bjec ec ect t t to to C C CYP YP YP2C 2C 2 8 8 8 an an nd d, d, to a le le less ss sser er er e ext xt ten en ent, t, C C CY YP YP2C 2C C9 9 9 m met et tab ab abol ol olis is ism m m a an and d d de de demo mo mons ns nstr tra a ate es s i i inc nc ncr r rea a ase se s d d d bi bi bioa oa o v va vai il ilab ab bil il i it it ity y y wi wi wit th th f f foo o od. d. 24 therefore, was designed to assess the safety and efficacy of oral treprostinil therapy in de novo PAH patients who were not concurrently receiving approved PAH therapy.
Methods

Study design
This was a 12-week, international, multi-center (Supplemental Table 1 ), randomized (2:1 oral treprostinil:placebo), double-blind, placebo-controlled study designed to evaluate the efficacy and safety of oral treprostinil in patients with PAH not currently receiving therapy (ERA, PDE-5I, or prostacyclin) for the treatment of PAH (www.clinicaltrials.gov; NCT00325403). The study was sponsored by United Therapeutics and conducted according to Good Clinical Practice principles. All study procedures were approved by an independent institutional review board and written informed consent was obtained from all patients prior to screening.
Patient population
Eligible patients were 12-75 years of age with idiopathic or hereditary PAH (IPAH/HPAH; including PAH associated with appetite suppressant/toxin use), PAH associated with repaired congenital systemic-to-pulmonary shunts (repaired 5 years), or PAH associated with collagen vascular disease (CVD) or human immunodeficiency virus (HIV). Patients were ineligible if they had received ERA, PDE-5I, or prostacyclin therapy within 30 days of baseline; or if they had evidence for significant left-sided heart disease or parenchymal lung disease. Baseline 6MWD was required to be between 100-450 meters (m). Patients were required to be optimally treated with conventional PAH therapies (e.g. anticoagulants, oral vasodilators, oxygen, digoxin, etc.) with no additions, discontinuations, or dose changes <14 days prior to baseline (excluding 5I, or prostacyclin) for the treatment of PAH (www.clinicaltrials.gov; NCT00325 25 540 40 03) 3) ). Th Th The e e st st s u udy y was sponsored by United Therapeutics and conducted according to Good Clinical Practice d d 6 changes to anticoagulants and diuretic dose adjustments)
Study endpoints
The primary endpoint was the effect of oral treprostinil on exercise capacity compared to placebo, as measured by the change in 6MWD from baseline to week 12. Secondary endpoints included: Borg dyspnea score; combined 6MWD/Borg dyspnea score (for detailed methods, 
Study drug
Study drug was provided as extended release, oral tablets in 0.125, 0.25, 0.5, and 1 mg strengths.
Study drug was originally initiated at 1.0 mg BID; however, based on tolerability issues identified in the FREEDOM-C study, 26 the study protocol was later amended to lower the starting dose to 0.5 mg BID and eventually 0.25 mg BID. Study drug was administered every 
Open-label extension
Patients who remained on study drug and completed all assessments during the 12-week treatment phase were eligible to be enrolled into an open-label extension trial. Additionally, placebo patients who experienced clinical worsening and were withdrawn from study drug prior to week 12 were also eligible for the open-label study assuming that they had completed all study assessments through week 12.
Statistical analysis
The primary analysis population or modified intent-to-treat (mITT) population was the population of patients with access to the 0.25 mg strength tablet at the time of randomization.
The intent-to-treat (ITT) population (as well as the safety population) was defined as all randomized patients. The per-protocol population was defined as randomized patients who completed at least the week 8 assessments or discontinued study drug due to documented clinical deterioration or non-accidental death, excluding major protocol violations. Study power calculations were originally performed for a sample size of approximately 150 patients.
Open-label extension
Patients who remained on study drug and completed all assessments during the 12-week r rea ea atm tm tme en ent t t ph ph pha a ase we we wer re eligible to be enrolled prematurely from the study or study drug for other reasons or who did not perform the 6MWT due to any reason not mentioned above (e.g., missed visit), provided that the patient performed at least one post-baseline 6MWT. Otherwise, the mean placebo rank or value corresponding to the geometric mean relative change for the placebo group was assigned.
Secondary endpoints were tested in the following order: trough 6MWD (week 11), time to clinical worsening, combined 6MWD and Borg, 6MWD at week 8, WHO functional class at magnitude of change in 6MWD) was estimated using the Hodges-Lehmann (H H-L -L L) ) me me medi di dian an an difference between treatment groups. For the primary endpoint, missing values and values postdi isc sc con on onti ti tinu nu uat at atio io ion of of of s stu t dy/study drug were handled ed ed u using imputatio o on n of f r r ran an anks for nonparametric n nfe e ere r ntial anal aly ys se es a and nd n i i imp mp mput ut uta at atio io on n n of of an n nalo ogo go ous M 6M 6MWD WD WD v val al a u ue ues s fo fo or de de d sc scri ript pt ptiv iv ive e st st tat at a is is i ti ti tics cs. . Th Th The o owe w west st st r ran ank k k o or or v va a alu ue ue c c cor or rre resp spon on o di di ding ng ng t to o th th the e e w w wors rs rst t t o o ove e era a all ll r r rel el ela a ativ iv ive e ch ch chan an ange ge e w w was as a ass ss ssig ig igne ne ned d f fo for r r de dea a ath h h within 12 we eek ek eks; s; s; d d dis is isco co ont n n in n nua ua uati t t on on on du du ue e to to to c c cli li l ni ni n ca ca cal l de de dete te eri r or or rat at atio io ion, n, n, t t tra ra rans s spl pl plan an anta ta tati ti ion on o , , or or or a a atr tr tria ia i l week 12, Borg score at week 12, dyspnea-fatigue at week 12, 6MWD at week 4, symptoms of PAH at week 12. Formal testing was terminated as soon as any p-value was above 0.05.
Descriptive statistics were used to evaluate safety endpoints; AEs were summarized for the ITT (safety) and mITT populations. Other safety endpoints (vital signs, ECGs, and laboratory parameters) were summarized using the ITT (safety) population. Data are presented as mean ± standard deviation (SD) or range; median (95% confidence interval [CI]); or percent. Statistical significance was considered to be two-sided p<0.05; statistical analysis was performed using SAS® software, version 9.2 (SAS Institute Inc., Cary, NC).
Results
Patient disposition is summarized in Figure 1 . Three-hundred-forty-nine patients (oral treprostinil, n=233; placebo, n=116) were randomized (ITT population); all patients received at least one dose of study drug. The mITT population consisted of 228 patients (oral treprostinil, n=151; placebo, n=77) who had access to the 0.25 mg study drug tablet at time of randomization and received at least one dose of study drug. For the mITT population, the mean (±SD) dose BID of study drug achieved in the oral treprostinil treatment group for patients completing the weeks 4, 8, and 12 assessments was 2.3±1.3 mg, 3.2±1.9 mg, and 3.4±1.9 mg, respectively (Figure 2) .
Baseline characteristics and patient disposition
For the mITT population, the mean age was 39.4 years (range: 12-73 years; Table 1 ). The majority of patients were Asian (71%) and female (73%), with a diagnosis of IPAH/HPAH (75%)(see Supplemental Table 2 for patient randomization by geographical region). Patients were predominantly WHO functional class III (66%) and the mean baseline 6MWD was 330 m.
Most patients were recently (<1 year; 86%) diagnosed with PAH. Patient demographics were
Results
Patient disposition is summarized in Figure 1 . Three-hundred-forty-nine patients (oral r rep ep pro ro rost st sti in inil il il, , , n n n=23 23 33 3; 3; placebo, n=116) were random om miz z zed (ITT popu ula la l tion on n) ) ); ; ; al a l patients received at Table 1) . Of the 228 patients in the mITT population, 125 oral treprostinil (83%) and 66 placebo patients (86%) completed the study (Figure 1) . to 41 m; p=0.0125). The 6MWD change from baseline at week 8 was also significantly improved (17.0 m; 95% CI: 1 to 33; p=0.0307). While improvements in 6MWD were noted at week 4 (12.0 m; 95% CI: 0 to 24 m; p=0.0518) and week 11 (13.0 m; 95% CI: -2 to 33; p=0.0653), these changes were not statistically significant (Figure 2) . The median change from baseline for the placebo treatment group was remarkably stable over the 12-week study period (range: -5 to 0 m).
For the ITT population, the change from baseline in 6MWD at week 12 was 26.0 m (95% CI: 10 to 41; p=0.0001). Significant improvements were also noted for week 4 (14. assessments increased as did the corresponding H-L treatment effects, indicating that larger treatment effects were associated with increasing study drug exposure and duration of treatment.
Secondary outcomes
For the mITT population, there was a significant improvement in the combined 6MWD/Borg analyses were performed for subgroups defined by patient demographics (age, se e ex, 
Safety
Adverse events for both the ITT and mITT populations are summarized in Table 3 . For the ITT population, the most common AEs reported in the oral treprostinil treatment group were headache (69%), nausea (39%), diarrhea (37%), pain in jaw (25%) and vomiting (24%). For the ITT population, headache, nausea, diarrhea, pain in jaw, flushing, and pain in extremity were reported more frequently (p<0.05) in the oral treprostinil treatment group as compared with the placebo group ( Table 3) . The most common AEs reported in patients receiving oral treprostinil therapy (ITT) that were considered severe in intensity were headache (40%), nausea (20%), diarrhea (13%), vomiting (12%), and pain in jaw (10%). Of these, headache and pain in jaw were reported more frequently (p<0.05) in the oral treprostinil group as compared to the placebo group (11% and 2%, respectively). Twenty-three oral treprostinil patients (10%) discontinued study drug due to AE in the ITT population. The most common prostacyclin AEs leading to study drug discontinuation among oral treprostinil patients (ITT) included headache, nausea, jaw pain, diarrhea, and vomiting. In the placebo group, 3 (3%) patients discontinued study drug due to AE.
The overall incidence and severity of AEs was similar for the mITT population, though fewer ).
There were 16 deaths in the ITT population, including 10 (4%) oral treprostinil patients and 6 (5%) placebo patients (Figure 1) . Additionally, one patient in the oral treprostinil group died after completing the week 12 visit but prior to enrolling in the open-label extension study.
Two deaths in the oral treprostinil group were considered by the individual investigator to be possibly attributable to study drug: one event of vasovagal syncope and one event of pulmonary edema. For the mITT population, there were 14 deaths, including 9 (6%) oral treprostinil patients and 5 (8%) placebo patients. Of the 9 oral treprostinil patients who died, 8 (5%) died prior to discontinuation of study drug (Figure 1) . 
Discussion
While the therapeutic benefits of inhaled and parenteral prostacyclin analogue therapies are wellestablished, the use of these therapies is complex and often challenging to administer. 8 As such, these therapies are typically reserved for use as part of a second-line, combination therapy (i.e.
inhaled plus ERA or PDE-5I) or the treatment of severe disease (parenteral). An oral prostacyclin analogue would add a first-line, prostacyclin-based treatment option to the PAH therapy armamentarium and could provide a viable initial treatment option for PAH patients with less severe disease.
In this study, PAH patients not receiving other therapy (ERA or PDE-5I) were randomized to oral treprostinil or placebo for 12 weeks. Significant improvements in 6MWD
were noted at week 12 for both the mITT and ITT populations and were observed by week 8 in the mITT population and week 4 in the ITT population. Importantly, 6MWD improvements were significantly increased at trough concentrations (week 11) for the ITT population and trended towards significance for the mITT population. While there were no formal dose-response or pharmacokinetic analyses performed in this study, there appeared to be a positive relationship between duration of treatment, dose of study drug achieved, and 6MWD treatment effect. In the current study, the average dose of oral treprostinil achieved by mITT patients completing the week 12 assessments was 3.4 mg. Previous pharmacokinetic data suggest that PAH patients treated with this dose of oral treprostinil would exhibit clinically-relevant serum treprostinil concentrations similar to those seen with parenteral infusion rates of approximately 10-30 ng/kg/min and similar to or greater than those seen with the recommended maintenance dose (54 μg QID) of inhaled treprostinil. 23, 27, 28 Over half (52%) of patients treated with oral treprostinil demonstrated at least a 20 m andomized to oral treprostinil or placebo for 12 weeks. Significant improvemen nt t ts i i in n 6M 6M 6MWD WD WD were noted at week 12 for both the mITT and ITT populations and were observed by week 8 in h he e mI mI mITT TT TT p p pop op opulat at atio io ion n and week 4 in the ITT popu pu ul la at tion. Important nt tly l , 6M 6M 6MWD W improvements were i i ign n nif i icantly in incr cr rea ase sed d d at at at t t tr ro roug ug ugh h co co con nc nce en ent trati io on n ns (we we week k 1 improvement in 6MWD at week 12, and 34% had an improvement of at least 50 m. These improvements are similar to those observed with the addition of inhaled treprostinil to background ERA or PDE-5I therapy (52% 20m; 31% 50 m). 16 Interestingly, the improvements seen in the placebo group for the current study (39% 20 m; 23% 50 m) are actually greater than those observed for the placebo group in the inhaled treprostinil study (32% 20 m; 12% 50 m), 16 despite the fact that placebo patients in the current study were not receiving background therapy. Together, these results further emphasize the need for placebo-controlled trials when the primary endpoint is 6MWD.
Oral treprostinil was generally well-tolerated in the mITT population and the incidence and severity of observed AEs were consistent with the previously observed effects of prostacyclin therapy (headache, nausea, diarrhea, flushing, and pain in jaw or extremity). 7, 13, 15, 16 There was no evidence of previously unidentified, treatment-limiting, oral administrationspecific AEs. It appears that the 0.25 mg BID starting dose in the mITT population was better tolerated (lower rate of discontinuation in the mITT population as compared to the ITT population, many of whom started on 1 mg BID.) This is consistent with the higher discontinuation rate in the original FREEDOM-C trial when the starting dose was 1 mg BID. 26 Future trials will focus on a starting dose of 0.25 mg to improve drug tolerance. It is important to note that the lower starting dose for the mITT population did not appear to limit patient dose-escalation to a clinically relevant range (3.4 mg at week 12), as demonstrated by the robust improvements in 6MWD. As mentioned above, the dose of oral treprostinil achieved by patients in the first 12 weeks of this study has been shown to produce plasma exposures similar to those demonstrated for low-dose parenteral or the recommended dose of inhaled treprostinil delivery. 23, 27, 28 and severity of observed AEs were consistent with the previously observed effect ct ts of o o prostacyclin therapy (headache, nausea, diarrhea, flushing, and pain in jaw or extremity). 7, 13, 15, 16 Th her er ere e e w wa was s s no no no evi vi id de den nce of previously unidentifie e ed d d, t t treatment-limit it ti i f f ng, , or or ora al administration- Overall, the results from this study with respect to 6MWD are similar to those seen in the placebo-controlled studies for currently approved oral therapies (both ERA and PDE-5I) that are typically used in the treatment of de novo PAH. [29] [30] [31] [32] In contrast to prior studies with bosentan, ambrisentan, and tadalafil, however, oral treprostinil had no effect on the incidence of clinical worsening. 29, 31, 32 Overall, the incidence of clinical worsening in this study was relatively low (10%) which may reflect the short duration of the study (12 weeks), the fairly large percentage of patients with WHO class II symptoms (34%), and the only moderately impaired exercise capacity across patients at baseline (mean 6MWD=330 m). Of note, the incidence of clinical worsening among placebo patients in this study (10%) was virtually identical to that reported for the 12-week studies for ambrisentan (ARIES-1; 9%) and sildenafil (SUPER; 10%), studies that also lacked a significant treatment effect with respect to clinical worsening 30, 31 and lower than that seen in the 12-week ARIES-2 (22%) and the longer duration BREATHE-1 (20% through week 28), two studies in which there were significant treatment effects for clinical worsening. 29, 31 It is also interesting that while the overall incidence of clinical worsening in this study was low, death was the most frequent clinical worsening event, with 8% and 6% of patients dying in the placebo and oral treprostinil groups, respectively. As a point of comparison, placebo deaths in the ARIES-1 and SUPER studies were 3% and 1%, respectively. This apparent discrepancy between incidence of clinical worsening and frequency of death may, in part, be explained by geographical differences between studies and the fact that the majority of patients in this study came from countries such as China in which advanced parenteral and organ transplant treatment options are less readily available (Supplemental Table 2 ). Related to this, it is also important to consider potential issues about the extrapolation of the efficacy results presented here to a more Western patient population. While the data are limited, recent analyses suggest that 6MWD he 12-week studies for ambrisentan (ARIES-1; 9%) and sildenafil (SUPER; 10 0% %) %), , stud ud udie ie ies s s th th tha at also lacked a significant treatment effect with respect to clinical worsening f f 30, 31 and lower than h hat at t s see ee een n in in in t t th h he 1 1 12-2-2-we w ek ARIES-2 (22%) and the he e lo o onger duration n B B BRE E EAT AT ATHE-1 (20% through w wee ek ek 28), two o st st tud ud die es s in n n w whi hi hich ch ch t the he here re re w w we ere s si ig gn nific ca a ant t tr tre ea eatm tm me en ent t ef ef ffe fect cts s s f fo or r c cl clin in inic ical al al w w wor or rse e eni n nin n ng. . f f treatment effects in Chinese patient populations are similar to those seen in Western populations and that survival rates for Chinese PAH patients have improved in the modern treatment era. [33] [34] [35] [36] In general, however, comparison of efficacy results across trials is highly problematic due to differences in patient population and study design and only properly addressed in head-to-head studies such as the ongoing AMBITION trial (www.clinicaltrials.gov NCT01178073) comparing two first-line, oral monotherapies (ambrisentan or tadalafil) with the respective combination therapy.
Study limitations
The conclusions drawn from this study are limited by the relatively short duration (12 weeks), the relative lack of patients with either less severe disease (WHO functional class I and/or 6MWD>450 m) or more severe disease (WHO functional class IV), the relatively small numbers of non-IPAH/HPAH patients, and the fact that study drug was evaluated as monotherapy only.
Longer duration studies are required to further address endpoints such as clinical worsening and survival, though these studies will likely have to rely on combination therapy with an active control group given the ethical issues of conducting a long-term placebo-controlled study in the context of a progressive and fatal disease. Similarly, more head-to-head studies are needed to directly compare the efficacy of available first-line oral therapies with distinct mechanisms of action.
Conclusions
Oral treprostinil is the first oral prostacyclin analogue to meet the primary endpoint in a randomized controlled trial in the PAH patient population. The results of this study support the use of oral treprostinil as initial therapy in PAH patients with class II or III symptoms. a alue es es shown as me mea a an (ra an ng nge) e) ), n n (% (% %) ), ), n n, or or o m me ea an n ±SD D D. P PAH H H= =p pulmo mo mona nar ry y a a art rter er ria al l hy hype pe ert ten ensi si ion on n; ; IP IPAH AH AH=i =id d diop p pat athi hi hic P PAH P P PAH H AH=hereditar ary y PA A AH H H; CVD VD VD=col ol lla lag ge g n n vasc scu ul lar r r dise e eas se; H HI IV V V=hu uma ma man n n im im mmun no nod defici i ien n ncy cy vir ir rus s; W WH WHO= O= O=W Wo orld d H He ealt r rga ga ani ni iza za z ti tion n; ; 6M 6M 6MWD WD D= =6 =6-m -mi in w wal a k k di dist st stan ance ce ce. . a a In In ncl l lud udes es s p pat atie ien n nts s fr fro om om I Ind nd di ia ( (mI mITT TT T, , n= n n 9 9 92) ) ) an and d d C Ch Chin ina a (m (m mIT TT, , n n=7 =71) ). . able 2. Clin n nic ic ical al al W W Wor or orse seni n ning ng ng. population consisted of all patients with access to 0.25 mg oral treprostinil tablets at randomization. There were 69 premature discontinuations in the ITT population (oral treprostinil, n=51; placebo, n=18) and 37 premature discontinuations in the mITT population (oral treprostinil, n=26; placebo, n=11). Most patients who prematurely discontinued study drug also prematurely discontinued the study prior to week 12 (ITT: oral treprostinil, n=32; placebo, n=12; mITT: oral treprostinil, n=20; placebo, n=9). 
